Skip to content

Study · Non-randomized trial · n = 6 · 1998

6 results

Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children.

Mericq V, Cassorla F, Salazar T, Avila A, Iñiguez G, Bowers CY, Merriam GR

The Journal of clinical endocrinology and metabolism1 Jul 1998Cited by 25 (Europe PMC)

PMID9661608 (opens in a new tab)DOI10.1210/jcem.83.7.4969 (opens in a new tab)PepBankPUB-09661608
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In prepubertal children with GH deficiency, GHRP‑2 produced a dose-wise increase in overnight GH secretion.

    In plain wordsIn children with growth hormone deficiency, GHRP‑2 raised overnight growth hormone release more as the dose went up.

    Peptide
    GHRP-2
    Outcome
    IncreaseOvernight GH secretion
    Study

    n = 6

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.3, 1.0 and 3.0 micrograms/kg/day in successive 2-month periods · subcutaneous · eight monthsAs given in this study (human).

    Source sentences

    Summary
    GHRP-2 administration produced a dosewise increase in overnight GH secretion.
    1 context sentence
    Summary · context
    Six prepubertal children with GHD and growth failure received stepwise increasing s.c. doses of GHRP-2, at 0.3, 1.0, and 3.0 micrograms/kg/day, in successive 2-month treatment periods, with monitoring of overnight 12 h episodic GH secretion and toxicity measures at the end of each period.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with GH deficiency, the GH effect of GHRP‑2 injections was relatively brief, with little effect on GH secretion later in the night.

    In plain wordsIn children with growth hormone deficiency, the GHRP‑2 effect on growth hormone was short, with little effect later in the night.

    Peptide
    GHRP-2
    Outcome
    No significant changeGH secretion later in the night
    Study

    n = 6

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.3, 1.0 and 3.0 micrograms/kg/day in successive 2-month periods · subcutaneous · eight monthsAs given in this study (human).

    Source sentences

    Summary
    GH profiles showed that the effect of GHRP-2 injections was relatively brief, with little effect upon GH secretion later in the night.
    1 context sentence
    Summary · context
    Six prepubertal children with GHD and growth failure received stepwise increasing s.c. doses of GHRP-2, at 0.3, 1.0, and 3.0 micrograms/kg/day, in successive 2-month treatment periods, with monitoring of overnight 12 h episodic GH secretion and toxicity measures at the end of each period.
  3. 03HumanNon-randomized trialEfficacy outcome

    In children with GH deficiency, serum IGF-I did not increase during GHRP‑2 treatment.

    In plain wordsIn children with growth hormone deficiency, GHRP‑2 did not raise IGF-I in the blood.

    Peptide
    GHRP-2
    Outcome
    No significant changeSerum IGF-I
    Study

    n = 6

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.3, 1.0 and 3.0 micrograms/kg/day in successive 2-month periods · subcutaneous · eight monthsAs given in this study (human).

    Source sentences

    Summary
    Serum levels of IGF-I and of IGFBP-3 did not increase.
    1 context sentence
    Summary · context
    Six prepubertal children with GHD and growth failure received stepwise increasing s.c. doses of GHRP-2, at 0.3, 1.0, and 3.0 micrograms/kg/day, in successive 2-month treatment periods, with monitoring of overnight 12 h episodic GH secretion and toxicity measures at the end of each period.
  4. 04HumanNon-randomized trialEfficacy outcome

    In children with GH deficiency, serum IGFBP-3 did not increase during GHRP‑2 treatment.

    In plain wordsIn children with growth hormone deficiency, GHRP‑2 did not raise IGFBP-3 in the blood.

    Peptide
    GHRP-2
    Outcome
    No significant changeSerum IGFBP-3
    Study

    n = 6

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.3, 1.0 and 3.0 micrograms/kg/day in successive 2-month periods · subcutaneous · eight monthsAs given in this study (human).

    Source sentences

    Summary
    Serum levels of IGF-I and of IGFBP-3 did not increase.
    1 context sentence
    Summary · context
    Six prepubertal children with GHD and growth failure received stepwise increasing s.c. doses of GHRP-2, at 0.3, 1.0, and 3.0 micrograms/kg/day, in successive 2-month treatment periods, with monitoring of overnight 12 h episodic GH secretion and toxicity measures at the end of each period.
  5. 05HumanNon-randomized trialEfficacy outcome

    In children with GH deficiency, growth velocity was higher during GHRP‑2 treatment than during pretreatment and post-treatment evaluations.

    In plain wordsIn children with growth hormone deficiency, growth was faster during GHRP‑2 treatment than before and after treatment.

    Peptide
    GHRP-2
    Outcome
    IncreaseGrowth velocity
    Study

    n = 6

    Comparator
    Pretreatment and post-treatment evaluations
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    0.3, 1.0 and 3.0 micrograms/kg/day in successive 2-month periods · subcutaneous · eight monthsAs given in this study (human).

    Source sentences

    Summary
    Growth velocity was higher during GHRP-2 treatment than during pretreatment and post-treatment evaluations.
    1 context sentence
    Summary · context
    Six prepubertal children with GHD and growth failure received stepwise increasing s.c. doses of GHRP-2, at 0.3, 1.0, and 3.0 micrograms/kg/day, in successive 2-month treatment periods, with monitoring of overnight 12 h episodic GH secretion and toxicity measures at the end of each period.
  6. 06HumanNon-randomized trialSafety outcome

    No side effects or toxicities were observed in six children with GH deficiency treated with GHRP‑2.

    In plain wordsIn children with growth hormone deficiency, no side effects or toxic effects were seen with GHRP‑2.

    Peptide
    GHRP-2
    Outcome
    No significant changeSide effects and toxicity
    Study

    n = 6

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.3, 1.0 and 3.0 micrograms/kg/day in successive 2-month periods · subcutaneous · eight monthsAs given in this study (human).

    Source sentences

    Summary
    There were no side effects or toxicities observed.
    1 context sentence
    Summary · context
    Six prepubertal children with GHD and growth failure received stepwise increasing s.c. doses of GHRP-2, at 0.3, 1.0, and 3.0 micrograms/kg/day, in successive 2-month treatment periods, with monitoring of overnight 12 h episodic GH secretion and toxicity measures at the end of each period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 2

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.